메뉴 건너뛰기




Volumn 11, Issue 2, 2015, Pages 323-331

Radium 223 dichloride: A multidisciplinary approach to metastatic castration-resistant prostate cancer

Author keywords

castration resistant prostate cancer; nuclear medicine physician; radiopharmaceuticals; radium 223 dichloride; emitting; emitting

Indexed keywords

ANALGESIC AGENT; CYCLOBUTANE DERIVATIVE; DOCETAXEL; ETHYLENEDIAMINE; ETHYLENEDIAMINE DERIVATIVE; HYDROXYAPATITE; OPIATE; RADIOPHARMACEUTICAL AGENT; RADIUM CHLORIDE RA 223; SAMARIUM 153; STRONTIUM 89; STRONTIUM CHLORIDE SR 89; ANTINEOPLASTIC AGENT; RADIOISOTOPE; RADIUM;

EID: 84921403242     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.157     Document Type: Review
Times cited : (6)

References (34)
  • 1
    • 79952408175 scopus 로고    scopus 로고
    • Enhancing prostate cancer care through the multidisciplinary clinic approach: A 15-year experience
    • Gomella LG, Lin J, Hoffman-Censits Jet al. Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J. Oncol. Pract. 6(6), e5-e10 (2010).
    • (2010) J. Oncol. Pract , vol.6 , Issue.6 , pp. e5-e10
    • Gomella, L.G.1    Lin, J.2    Hoffman-Censits, J.3
  • 2
    • 84903476624 scopus 로고    scopus 로고
    • Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases
    • Zustovich F, Fabiani F. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. Crit. Rev. Oncol. Hematol. 9(2), 197-209 (2014).
    • (2014) Crit. Rev. Oncol. Hematol , vol.9 , Issue.2 , pp. 197-209
    • Zustovich, F.1    Fabiani, F.2
  • 4
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369(3), 213-223 (2013).
    • (2013) N. Engl. J. Med , vol.369 , Issue.3 , pp. 213-223
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 6
    • 84890531221 scopus 로고    scopus 로고
    • Radiometabolic treatment of bone-metastasizing cancer: From 186rhenium to 223radium
    • Rubini G, Nicoletti A, Rubini D, Asabella AN. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. Cancer Biother. Radiopharm. 29(1), 1-11 (2014).
    • (2014) Cancer Biother. Radiopharm , vol.29 , Issue.1 , pp. 1-11
    • Rubini, G.1    Nicoletti, A.2    Rubini, D.3    Asabella, A.N.4
  • 7
    • 84881294465 scopus 로고    scopus 로고
    • Recent advances revolutionize treatment of metastatic prostate cancer
    • Madan RA, Arlen PM. Recent advances revolutionize treatment of metastatic prostate cancer. Future Oncol. 9(8), 1133-1144 (2013).
    • (2013) Future Oncol , vol.9 , Issue.8 , pp. 1133-1144
    • Madan, R.A.1    Arlen, P.M.2
  • 8
    • 84888303650 scopus 로고    scopus 로고
    • Targeted α-particle therapy of bone metastases in prostate cancer
    • Jadvar H, Quinn DI. Targeted α-particle therapy of bone metastases in prostate cancer. Clin. Nucl. Med. 38(12), 966-971 (2013).
    • (2013) Clin. Nucl. Med , vol.38 , Issue.12 , pp. 966-971
    • Jadvar, H.1    Quinn, D.I.2
  • 9
    • 84860201679 scopus 로고    scopus 로고
    • An alpha edge?
    • Silberstein EB. An alpha edge? Oncology 26(4), 345-348 (2012).
    • (2012) Oncology , vol.26 , Issue.4 , pp. 345-348
    • Silberstein, E.B.1
  • 10
    • 0025950294 scopus 로고
    • Rhenium-186(sn)hedp for treatment of painful osseous metastases: Results of a double-blind crossover comparison withplacebo rhenium-186(sn)hedp for treatment of painful osseous metastases
    • Maxon HR, Schroder LE, Hertzberg VS et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison withplacebo rhenium-186(Sn)HEDP for treatment of painful osseous metastases. J. Nucl. Med. 32, 1877-1881 (1991).
    • (1991) J. Nucl. Med , vol.32 , pp. 1877-1881
    • Maxon, H.R.1    Schroder, L.E.2    Hertzberg, V.S.3
  • 11
    • 84921413128 scopus 로고    scopus 로고
    • Quadramet prescribing information. http://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=61e84808-0999-4923-910c-2a480d5f971a&type=pdf&name=61e84808-0999-4923-910c-2a480d5f971a
    • Quadramet Prescribing Information
  • 12
    • 83455195239 scopus 로고    scopus 로고
    • Radiopharmaceuticals for painful bone metastases: Perspective from radiation oncology
    • Barnes EA. Radiopharmaceuticals for painful bone metastases: perspective from radiation oncology. J. Support. Oncol. 9(6), 208-209 (2011).
    • (2011) J. Support. Oncol , vol.9 , Issue.6 , pp. 208-209
    • Barnes, E.A.1
  • 13
    • 83455244321 scopus 로고    scopus 로고
    • Radiopharmaceuticals: When and how to use them to treat metastatic bone pain
    • Paes FM, Ernani V, Hosein P, Serafini AN. Radiopharmaceuticals: when and how to use them to treat metastatic bone pain. J. Support. Oncol. 9(6), 197-205 (2011).
    • (2011) J. Support. Oncol , vol.9 , Issue.6 , pp. 197-205
    • Paes, F.M.1    Ernani, V.2    Hosein, P.3    Serafini, A.N.4
  • 14
    • 0042887586 scopus 로고    scopus 로고
    • Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Tandomized phase ii trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate
    • Palmedo H, Manka-Waluch A, Albers P et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized Phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J. Clin. Oncol. 21(15), 2869-2875 (2003).
    • (2003) J. Clin. Oncol , vol.21 , Issue.15 , pp. 2869-2875
    • Palmedo, H.1    Manka-Waluch, A.2    Albers, P.3
  • 15
    • 0035798930 scopus 로고    scopus 로고
    • Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase ii trial
    • Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised Phase II trial. Lancet 357(9253), 336-341 (2001).
    • (2001) Lancet , vol.357 , Issue.9253 , pp. 336-341
    • Tu, S.M.1    Millikan, R.E.2    Mengistu, B.3
  • 16
    • 34250368094 scopus 로고    scopus 로고
    • Clinical benefit of bone-targeted radiometabolic therapy with 153sm-edtmp combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer
    • Ricci S, Boni G, Pastina I et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 34(7), 1023-1030 (2007).
    • (2007) Eur. J. Nucl. Med. Mol. Imaging , vol.34 , Issue.7 , pp. 1023-1030
    • Ricci, S.1    Boni, G.2    Pastina, I.3
  • 17
    • 84889252465 scopus 로고    scopus 로고
    • Safety and antitumor efficacy of (153)sm-edtmp and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer
    • Borso E, Boni G, Pastina I et al. Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer. Nucl. Med. Comm. 35(1), 88-94 (2014).
    • (2014) Nucl. Med. Comm , vol.35 , Issue.1 , pp. 88-94
    • Borso, E.1    Boni, G.2    Pastina, I.3
  • 18
    • 84921409492 scopus 로고    scopus 로고
    • The samdocet study: 153sm-edtmp and docetaxel versus docetaxel in taxane-naive patients with metastatic castration-refractory prostatecancer
    • Borso E, Mazzarri S, Boni G et al. The SAMDOCET study: 153Sm-EDTMP and docetaxel versus docetaxel in taxane-naive patients with metastatic castration-refractory prostatecancer. Eur. J. Nucl. Med. Mol. Imaging. 40, S497-S497 (2013).
    • (2013) Eur. J. Nucl. Med. Mol. Imaging , vol.40 , pp. S497-S497
    • Borso, E.1    Mazzarri, S.2    Boni, G.3
  • 19
    • 84901638475 scopus 로고    scopus 로고
    • Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial
    • Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a Phase 3, double-blind, randomised trial. Lancet Oncol. 15(7), 738-746 (2014).
    • (2014) Lancet Oncol , vol.15 , Issue.7 , pp. 738-746
    • Sartor, O.1    Coleman, R.2    Nilsson, S.3
  • 20
    • 84887409151 scopus 로고    scopus 로고
    • Urological cancer: Alpha-emitting radium-223-additional choices, more unknowns
    • Higano C. Urological cancer: alpha-emitting radium-223-additional choices, more unknowns. Nat. Rev. Clin. Oncol. 10(11), 612-613 (2013).
    • (2013) Nat. Rev. Clin. Oncol , vol.10 , Issue.11 , pp. 612-613
    • Higano, C.1
  • 21
    • 84921343437 scopus 로고    scopus 로고
    • Alpha-emitter radium-223 in the management of solid tumors: Current status and future directions
    • Nilsson S. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions. Am. Soc. Clin. Oncol. Educ. Book 34l, e132-e139 (2014).
    • (2014) Am. Soc. Clin. Oncol. Educ. Book , vol.341 , pp. e132-e139
    • Nilsson, S.1
  • 22
    • 46949111791 scopus 로고    scopus 로고
    • Alpha-particles for targeted therapy
    • Sgouros G. Alpha-particles for targeted therapy. Adv. Drug Deliv. Rev. 60(12), 1402-1406 (2008).
    • (2008) Adv. Drug Deliv. Rev , vol.60 , Issue.12 , pp. 1402-1406
    • Sgouros, G.1
  • 23
    • 41949104346 scopus 로고    scopus 로고
    • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
    • Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26(7), 1148-1159 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.7 , pp. 1148-1159
    • Scher, H.I.1    Halabi, S.2    Tannock, I.3
  • 24
    • 84891835413 scopus 로고    scopus 로고
    • Visceral disease in castration-resistant prostate cancer
    • Pezaro CJ, Omlin A, Lorente D et al. Visceral disease in castration-resistant prostate cancer. Eur. Urol. 65(2), 270-273 (2014).
    • (2014) Eur. Urol , vol.65 , Issue.2 , pp. 270-273
    • Pezaro, C.J.1    Omlin, A.2    Lorente, D.3
  • 25
    • 84900503061 scopus 로고    scopus 로고
    • Safety of radium-223 dichloride (ra-223) with docetaxel (d) in patients with bone metastases from castration-resistant prostate cancer (crpc): A phase i prostate cancerclinical trials consortium study
    • Abstract 5021
    • Michael J, Morris HJH, Sweeney C et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a Phase I Prostate Cancerclinical Trials Consortium study. J. Clin. Oncol. 31(Suppl.), Abstract 5021 (2013).
    • (2013) J. Clin. Oncol , vol.31
    • Michael, J.1    Morris, H.J.H.2    Sweeney, C.3
  • 31
    • 84901852798 scopus 로고    scopus 로고
    • To treat or not to treat, that is the question: The role of bone-targeted therapy in metastatic prostate cancer
    • Higano CS. To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer. J. Clin. Oncol. 32(11), 1107-1111 (2014).
    • (2014) J. Clin. Oncol , vol.32 , Issue.11 , pp. 1107-1111
    • Higano, C.S.1
  • 34
    • 84907164048 scopus 로고    scopus 로고
    • Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: Samarium-153-edtmp and radium-223
    • Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and Radium-223. Adv. Exp. Med. Biol. 804, 291-304 (2014).
    • (2014) Adv. Exp. Med. Biol , vol.804 , pp. 291-304
    • Anderson, P.M.1    Subbiah, V.2    Rohren, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.